Insight journal - Therapy

Cardiovascular partnering – recent deal analysis 2007-2013

Posted on 18 September 2013

Tags: , ,

Partnering deal analysis in the last decade has seen an increase in cardiovascular partnering with an increase in modern diagnostic technologies.

Cardiovascular disease is a class of disease that affects the heart and blood vessels (collectively the cardiac system).

According to Current Agreements, cardiovascular partnering has been one of the most widely chosen therapeutic area with more than 1000 partnering deals announced since 2007.  This cardiovascular deal making activity is commonly found among big pharma and biotech, smaller healthcare industries and academic institutions.

The data in this article has been sourced from the newly published Cardiovascular Partnering Terms and Agreements report

The following figure shows cardiovascular partnering deal analysis frequency between 2007 and mid September 2013.

Figure 1: Cardiovascular partnering since 2007

fig1

 

 

 

 

 

 

 

Source: Current Agreements, 2013

It is evident that partnering activity has been varied since 2007. As we enter into the month of September, this year has seen 126 cardiovascular partnering deals suggesting many more to come this year.

According to Current Agreements, big pharma and big biotech and biotech companies are very active in cardiovascular deal making. However, pharmaceutical companies have been the most active in recent years collaborating with several big pharma companies in the development stage of compounds.

An example to cite would be the recent deal where Thoratec acquired Duraheart ventricular assist system from Terumo for a total of $56.5 million comprising upfront and milestone payments…click here for more on this deal.

The following figure provides an overview of cardiovascular partnering deal analysis by major industry sector since 2007

Figure 2: Cardiovascular partnering by industry sector since 2007

fig2

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2013

Analysis from our Current Agreements database, suggests that the vast majority or deals are made at the marketed stage showing promise in the disease treatment and more drugs in the market in this area.

Figure 3: Cardiovascular partnering by stage of development since 2007

fig3

 

 

 

 

 

 

 

Source: Current Agreements, 2013

Cardiovascular, being an exciting and thriving area showing promise in better treatments, can have a high headline deal value.

The following figure shows the leading cardiovascular deals by headline value of the deal when announced between 2007 and 2013.

 Figure 4: Top Cardiovascular deals by value since 2007

fig4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2013

Cardiovascular partnering is often targeted towards one of more specific cardiovascular indications. Some of the popular and commonly partnered cardiovascular therapeutics indications are congestive heart failure, coronary artery disease and hypertension. The following figure illustrates all the individual cardiovascular therapeutic indications recorded in our database.

Figure 5: Cardiovascular partnering by individual therapeutics area since 2007

fig5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Source: Current Agreements, 2013

Figure 6: Most active cardiovascular dealmakers

The following list provides an insight into the most active dealmakers in cardiovascular partnering between 2007 and mid September 2013.

fig6

 

 

 

 

 

 

 

 

Source: Current Agreements, 2013

Details of the deals entered by these companies can be viewed in detail on subscription to our database Current Agreements.

The Cardiovascular Partnering Terms and Agreements  report published by Current Partnering provides full details of over 1,300 cardiovascular deals announced since 2007 and includes average deal terms including headline, upfront, milestone and royalty rates, where available. In addition, the report provides details of deals broken down by deal type, stage of development, company A-Z, specific individual therapy area and technology type. More details here

There is a huge expectation in the advancement and development of biomarkers as it shows promise in personalized treatment. It would be interesting to witness the deal making activity and trends in this sector in the coming years.

Sources

The above information has been abstracted from the following resources:

Shamini Thiagarajan

 

Related

Read: more cardiovascular deals in pharma, biotech, life science partnering deal news, insights and glossary

View: glossary definition for cardiovascular partnering

Report: Cardiovascular Partnering Terms and Agreements

View also: Other specific cardiovascular indication reports

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cabannerad300x150new4gif
rauconbadgejpg
e78banner300x150animgif